Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models

American Journal of Physiology - Renal Physiology

Volumn 285, Issue 6 54-6, 2003, Pages

  Zeisberg, Michael ^a   Bottiglio, Cindy ^a   Kumar, Navin ^a   Maeshima, Yohei ^a   Strutz, Frank ^b   Müller, Gerhard A ^b   Kalluri, Raghu ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

Fibroblasts; Matrix metalloproteinases; Osteogenic protein 1; Tubulointerstitial fibrosis

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE A; MATRIX METALLOPROTEINASE; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

ALPHA CHAIN; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; FIBROBLAST; GENETIC ASSOCIATION; GENETIC MODEL; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; MESANGIUM CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; URETHRA OBSTRUCTION;

EID: 0242582117     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00191.2002     Document Type: Article

References (58)

1. Andrews KL, Mudd JL, Li C, and Miner JH. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 160: 721-730, 2002.
2. Aros C and Remuzzi G. The renin-angiotensin system in progression, remission and regression of chronic nephropathies. J Hypertens 20 Suppl 3: S45-S53, 2002.
3. Badid C, Vincent M, Fouque D, Laville M, and Desmouliere A. Myofibroblast: a prognostic marker and target cell in progressive renal disease. Ren Fail 23: 543-549, 2001.
4. Becker GJ and Hewitson TD. The role of tubulointerstitial injury in chronic renal failure. Curr Opin Nephrol Hypertens 9: 133-138, 2000.
5. Bohle A, Christ H, Grund KE, and Mackensen S. The role of the interstitium of the renal cortex in renal disease. Contrib Nephrol 16: 109-114, 1979.
6. Border WA and Noble NA. Targeting TGF-β for treatment of disease. Nat Med 1: 1000-1001, 1995.
7. Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest 110: 1753-1758, 2002.
8. Brinckerhoff CE and Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 3: 207-214, 2002.
9. Bruns FJ, Seddon P, Saul M, and Zeidel ML. The cost of caring for end-stage kidney disease patients: an analysis based on hospital financial transaction records. J Am Soc Nephrol 9: 884-890, 1998.
10. Chen EI, Kridel SJ, Howard EW, Li W, Godzik A, and Smith JW. A unique substrate recognition profile for matrix metalloproteinase-2. J Biol Chem 277: 4485-4491, 2002.
11. Cohen PL and Eisenberg RA. Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9: 243-269, 1991.
12. Dudley AT, Lyons KM, and Robertson EJ. A requirement for bone morphogenetic protein-7 during development of the mammalian kidney and eye. Genes Dev 9: 2795-2807, 1995.
13. Eddy AA. Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 7: 2495-2508, 1996.
14. El Nahas A. Mechanisms of experimental and clinical renal scarring. In: Oxford Textbook of Clinical Nephrology (2nd ed.), edited by Davison A, Cameron J, Grunfeld J, Kerr D, Ritz E, and Winearls C. Oxford, UK: Oxford University Press, 1998, p. 1749-1788.
15. Fogo AB. The potential for regression of renal scarring. Curr Opin Nephrol Hypertens 12: 223-225, 2003.
16. Fogo AB. Pathology of progressive nephropathies. Curr Opin Nephrol Hypertens 9: 241-246, 2000.
17. Gould SE, Day M, Jones SS, and Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int 61: 51-60, 2002.
18. Hebert LA, Wilmer WA, Falkenhain ME, Ladson-Wofford SE, Nahman NS, and Rovin BH. Renoprotection: one or many therapies? Kidney Int 59: 1211-1226, 2001.
19. Herzlinger D. Renal interstitial fibrosis: remembrance of things past? J Clin Invest 110: 305-306, 2002.
20. Hogan BL. Bone morphogenetic proteins in development. Curr Opin Genet Dev 6: 432-438, 1996.
21. Hruska KA, Guo G, Wozniak M, Martin D, Miller S, Liapis H, Loveday K, Klahr S, Sampath TK, and Morrissey J. Osteogenic protein-1 prevents renal fibrogenesis associated with ureteral obstruction. Am J Physiol Renal Physiol 279: F130-F143, 2000.
22. Iwano M, Plieth D, Danoff TM, Xue C, Okada H, and Neilson EG. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110: 341-350, 2002.
23. Kelley VE and Roths JB. Interaction of mutant lpr gene with background strain influences renal disease. Clin Immunol Immunopathol 37: 220-229, 1985.
24. Klahr S, Morrissey J, Hruska K, Wang S, and Chen Q. New approaches to delay the progression of chronic renal failure. Kidney Int Suppl: 23-26, 2002.
25. Komers R and Anderson S. Optimal strategies for preventing progression of renal disease: should angiotensin-converting enzyme inhibitors and angiotensin receptor blockers be used together? Curr Hypertens Rep 2: 465-472, 2000.
26. Kridel SJ, Chen E, Kotra LP, Howard EW, Mobashery S, and Smith JW. Substrate hydrolysis by matrix metalloproteinase-9. J Biol Chem 276: 20572-20578, 2001.
27. Lonnemann G, Shapiro L, Engler-Blum G, Muller GA, Koch KM, and Dinarello CA. Cytokines in human renal interstitial fibrosis. I. Interleukin-1 is a paracrine growth factor for cultured fibrosis-derived kidney fibroblasts. Kidney Int 47: 837-844, 1995.
28. Luo G, Hofmann C, Bronckers AL, Sohocki M, Bradley A, and Karsenty G. BMP-7 is an inducer of nephrogenesis and is also required for eye development and skeletal patterning. Genes Dev 9: 2808-2820, 1995.
29. Maeshima Y, Kashihara N, Sugiyama H, Makino H, and Ota Z. Antisense oligonucleotides to proliferating cell nuclear antigen and Ki-67 inhibit human mesangial cell proliferation. J Am Soc Nephrol 7: 2219-2229, 1996.
30. 3(IV): implications for Alport syndrome. J Cell Biol 135: 1403-1413, 1996.
31. Morrissey J, Hruska K, Guo G, Wang S, Chen Q, and Klahr S. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol 13 Suppl 1: S14-S21, 2002.
32. Muller GA, Frank J, Rodemann HP, and Engler-Blum G. Human renal fibroblast cell lines (tFKIF and tNKF) are new tools to investigate pathophysiologic mechanisms of renal interstitial fibrosis. Exp Nephrol 3: 127-133, 1995.
33. Murphy M, McMahon R, Lappin DW, and Brady HR. Gremlins: is this what renal fibrogenesis has come to? Exp Nephrol 10: 241-244, 2002.
34. Ozkaynak E, Rueger DC, Drier EA, Corbett C, Ridge RJ, Sampath TK, and Oppemann H. OP-1 cDNA encodes an osteogenic protein in the TGF-β family. EMBO J 9: 2085-2093, 1990.
35. Pastan S and Bailey J. Dialysis therapy. N Engl J Med 338: 1428-1437, 1998.
36. Pavlova A, Stuart RO, Pohl M, and Nigam SK. Evolution of gene expression patterns in a model of branching morphogenesis. Am J Physiol Renal Physiol 277: F650-F663, 1999.
37. Peters H, Border WA, and Noble NA. Targeting TGF-β overexpression: maximizing the antifibrotic actions of angiotensin II blockade in anti-Thy1 glomerulonephritis. Nephrol Dial Transplant 14: 22-23, 1999.
38. Raij L, Azar S, and Keane W. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26: 137-143, 1984.
39. Remuzzi G and Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998.
40. Sakurai H and Nigam SK. In vitro branching tubulogenesis: implications for developmental and cystic disorders, nephron number, renal repair, and nephron engineering. Kidney Int 54: 14-26, 1998.
41. Schedl A and Hastie ND. Cross-talk in kidney development. Curr Opin Genet Dev 10: 543-549, 2000.
42. Simon M, Maresh JG, Harris SE, Hernandez JD, Arar M, Olson MS, and Abboud HE. Expression of bone morphogenetic protein-7 mRNA in normal and ischemic adult rat kidney. Am J Physiol Renal Physiol 276: F382-F389, 1999.
43. Strutz F, Heeg M, Kochsiek T, Siemers G, Zeisberg M, and Muller GA. Effects of pentoxifylline, pentifylline and γ-interferon on proliferation, differentiation, and matrix synthesis of human renal fibroblasts. Nephrol Dial Transplant 15: 1535-1546, 2000.
44. Strutz F and Muller GA. Interstitial pathomechanisms underlying progressive tubulointerstitial damage. Kidney Blood Press Res 22: 71-80, 1999.
45. Strutz F, Zeisberg M, Hemmerlein B, Sattler B, Hummel K, Becker V, and Muller GA. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int 57: 1521-1538, 2000.
46. Strutz F, Zeisberg M, Renziehausen A, Raschke B, Becker V, van Kooten C, and Muller G. TGF-β1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2). Kidney Int 59: 579-592, 2001.
47. Timoshanko JR, Kitching AR, Holdsworth SR, and Tipping PG. Interleukin-12 from intrinsic cells is an effector of renal injury in crescentic glomerulonephritis. J Am Soc Nephrol 12: 464-471, 2001.
48. Vu TH and Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev 14: 2123-2133, 2000.
49. Vukicevic S, Basic V, Rogic D, Basic N, Shih MS, Shepard A, Jin D, Dattatreyamurty B, Jones W, Dorai H, Ryan S, Griffiths D, Maliakal J, Jelic M, Pastorcic M, Stavljenic A, and Sampath TK. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 102: 202-214, 1998.
50. Vukicevic S, Kopp JB, Luyten FP, and Sampath TK. Induction of nephrogenic mesenchyme by osteogenic protein 1 (bone morphogenetic protein 7). Proc Natl Acad Sci USA 93: 9021-9026, 1996.
51. Vukicevic S, Latin V, Chen P, Batorsky R, Reddi AH, and Sampath TK. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: high-affinity binding to basement membranes. Biochem Biophys Res Commun 198: 693-700, 1994.
52. Wang S, Chen Q, Simon TC, Strebeck F, Chaudhary L, Morrissey J, Liapis H, Klahr S, and Hruska KA. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int 63: 2037-2049, 2003.
53. Wang S and Hirschberg R. BMP7 antagonizes TGF-β-dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 284: F1006-F1013, 2003.
54. Wang SN, Lapage J, and Hirschberg R. Loss of tubular bone morphogenetic protein-7 in diabetic nephropathy. J Am Soc Nephrol 12: 2392-2399, 2001.
55. Yu L, Noble NA, and Border WA. Therapeutic strategies to halt renal fibrosis. Curr Opin Pharmacol 2: 177-181, 2002.
56. Zeisberg M, Hanai J, Sugimoto H, Mammoto T, Charytan D, Strutz F, and Kalluri R. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9: 964-968, 2003.
57. Zeisberg M, Maeshima Y, Mosterman B, and Kalluri R. Renal fibrosis: extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol 160: 2001-2008, 2002.
58. Zeisberg M, Strutz F, and Muller GA. Role of fibroblast activation in inducing interstitial fibrosis. J Nephrol 13 Suppl 3: S111-S120, 2000.